References: 1. Lieberman JA, First MB. Psychotic Disorders. N Engl J Med. 2018;379(3):270-280. doi:10.1056/NEJMra1801490 2. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43-62. doi:10.2147/PROM.S42735 3. Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024;264:1-28. doi:10.1016/j.schres.2023.11.015 4. Stürup AE, Hjorthøj C, Jensen HD, et al. Self-reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first-episode schizophrenia. Early Interv Psychiatry. 2023;17(10):974-983. doi:10.1111/eip.13389 5. Whale R, Harris M, Kavanagh G, et al. Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study. BJPsych Open. 2016;2(5):323-329. doi:10.1192/bjpo.bp.116.002766 6. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-356. doi:10.1002/wps.20567 7. Maravic MC, Birch K, Nguyen ATH, et al. Quantifying the tolerability of antipsychotic treatment-related side effects in schizophrenia: a survey study of patients and caregiver proxies. Patient Prefer Adherence. 2025;19:2821-2834. doi:10.2147/PPA.S466742 8. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147-154. doi:10.4088/PCC.08r00612
Side effects and insufficient symptom control can hinder newly diagnosed patients from staying on therapy within the first few months of treatment initiation.4,5
